查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1944482

全球藥物減敏市場：產業分析、市場規模、佔有率及按類型、最終用戶、銷售管道、國家和地區分類的預測（2025-2032 年）

Drug Desensitization Market, By Type, By End-Users, By Sales Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 328 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年藥物脫敏市場規模價值 6.021 億美元，從 2025 年到 2032 年將以 8.07% 的複合年成長率成長。

藥物脫敏市場涵蓋旨在暫時提高已知存在藥物過敏或超敏反應患者對關鍵藥物耐受性的治療性介入和結構化臨床通訊協定，使患者能夠在受控的醫療環境中繼續接受治療。藥物過敏的日益普遍以及對抗生素、化療藥物和生物製藥等第一線治療藥物的依賴性不斷增強，是嚴重市場成長的主要因素。一個關鍵的市場趨勢是轉向以先進診斷工具和病患監測技術為支撐的個人化、基於通訊協定的脫敏策略。然而，對訓練有素的醫療專業人員的需求、嚴格的臨床監督以及相關的高昂治療成本是主要的阻礙因素。儘管有這些限制，但臨床醫生意識的提高以及生物製藥和腫瘤療法的日益普及，為醫院和專科醫療機構廣泛採用標準化脫敏方案提供了巨大的機會。

藥物脫敏的市場動態

藥物過敏反應呈上升趨勢

藥物超敏反應發生率的不斷上升是推動全球藥物減敏療法需求成長的主要因素。隨著製藥業不斷擴展至新的治療領域，越來越多的患者在使用包括抗生素、化療藥物和生物製藥在內的基本藥物時出現免疫介導的不良反應。這些超敏反應的嚴重程度差異很大，從輕微的皮疹到危及生命的嚴重過敏反應，為有效且持續的治療帶來了巨大挑戰。根據2023年3月發表的一篇題為「過敏性疾病的發病機制及其對治療性介入的影響」的綜述，藥物超敏反應約佔所有藥物不良反應的5%至10%，影響全球約7%至10%的人口。約8%的個體報告有藥物過敏史，但確診病例則少得多。在兒童族群中，疑似超敏反應佔1%至2%，確診病例約佔0.05%。抗生素仍然是最常見的誘發因素，導致約 30% 的嚴重反應，包括史蒂文斯-約翰遜症候群。

藥物減敏市場：細分分析

全球市場已根據類型、最終用戶、銷售管道和地區進行了市場細分。

按類型分類，舌下免疫療法（SLIT）憑藉其眾多以患者為中心的優勢，目前在全球藥物脫敏市場中佔據領先地位，預計到2025年將佔66.1%的市場佔有率。對患者而言，最顯著的益處在於過敏原萃取物或治療藥物透過舌下給藥，使患者能夠在家中輕鬆舒適地進行治療，從而避免頻繁就醫。

2023年10月，美國過敏、氣喘和免疫學會（AAAAI）報告稱，舌下免疫療法（SLIT）在三年內使花生過敏兒童的脫敏率達到60%，緩解率達到48%。研究表明，幼兒早期療育是促進藥物減敏和長期過敏緩解的關鍵因素。

醫院和專科過敏診所是全球藥物減敏市場最大的終端用戶。這一優勢源於它們能夠在受控的醫療環境中整合先進的診斷能力、專業的臨床知識和多學科患者管理。這些機構憑藉其獨特的優勢，能夠透過個人化的給藥通訊協定、持續的病患監測監測以及免疫學家和過敏學家的密切監督，提供安全、精準且循證的藥物脫敏治療。先進脫敏療法的監管核准也凸顯了醫院和專科診所在該領域的重要性。例如，2024年2月，美國食品藥物管理局（FDA）核准了由基因泰克和諾華公司聯合研發的Zolaia（Omalizumab），這是第一個被證實能夠減少意外接觸多種食物後過敏反應的藥物。這項核准將適應症擴大到 1 歲及以上兒童和患有 IgE 介導的食物過敏的成年人，凸顯了醫院和專科診所在提供和管理高級脫敏療法方面發揮的關鍵作用。

藥物脫敏市場—區域分析

預計到2025年，北美將在全球藥物脫敏市場佔據關鍵地位。這得歸功於其高度發展的醫療基礎設施、許多製藥和生物技術公司，以及政府支持過敏管理和免疫耐受療法創新的政策。此外，該地區還受益於公共和私人研發投入的顯著成長，這持續推動著治療方法的進步和臨床應用。例如，2025年9月，總部位於美國的生物製藥公司ARS Pharmaceuticals在日本獲得了Nefy的監管核准。 Nefy是全球首款也是目前唯一一款用於緊急治療過敏反應和過敏性休克的無針腎上腺素滴鼻劑。該產品由ARS與Alfresa Holdings Corporation共同開發，將由ARS在日本銷售，預計將於2025年第四季開始針對體重15公斤及以上的成人和兒童患者上市。

美國藥物脫敏市場—國家分析

美國藥物脫敏市場仍然是全球最大的，這得益於其在研發方面的巨額投資、先進的醫療基礎設施以及患者中較高的藥物和食物過敏患病率。諸如再生元製藥（Regeneron Pharmaceuticals）和地平線治療公司（Horizo​​​​n Therapeutics）等大型製藥公司的強大影響力，以及許多成熟的專業過敏治療中心，正在加速先進脫敏方案在美國的推廣通訊協定。例如，2023年9月，雀巢將其花生過敏治療藥物Palforzia出售給了美國公司Stallergenes Glia，該公司在過敏原免疫療法和藥物脫敏領域享有盛譽。 Palforzia是首個核准的口服花生過敏治療藥物，於2020年被雀巢以21億美元收購，但其商業性應用仍有限。這項收購使 Stallergenes Glia 成為第一家提供呼吸道和食物過敏治療的公司，使雀巢能夠將其策略重點重新集中到胃腸道治療上。

目錄

第1章 藥物脫敏市場概覽

  • 調查範圍
  • 市場預測期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：藥物減敏治療的關鍵市場趨勢

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 未來市場趨勢

第4章：藥物減敏工作場所調查

  • PEST分析
  • 波特五力分析
  • 成長前景分析
  • 法規結構分析

第5章 藥物減敏市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章 藥物脫敏市場現狀

  • 藥物脫敏市佔率分析（2024 年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

7. 藥物脫敏市場按類型分類

  • 概述
    • 細分市場佔有率分析：按類型
    • 皮下免疫療法（SCIT）
    • 舌下免疫療法（SLIT）
    • 其他新的免疫療法遞送方法

8. 按最終用戶分類的藥物脫敏市場

  • 概述
    • 細分市場佔有率分析：依最終用戶分類
    • 門診治療中心
    • 醫院和專門的過敏診所
    • 居家醫療
    • 其他

9. 按銷售管道分類的藥物脫敏市場

  • 概述
    • 細分市場佔有率分析：依銷售管道分類
    • 線上管道
    • 離線頻道

10. 各地區藥物減敏市場

  • 介紹
  • 北美洲
    • 概述
    • 北美主要製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲主要製造商
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他
  • 亞太地區
    • 概述
    • 亞太地區主要製造商
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲的主要製造商
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他

第11章 主要供應商分析—藥物脫敏產業

  • 競爭對手儀錶板
    • 競爭基準
    • 競爭定位
  • 公司簡介
    • IDEXX Laboratories Inc
    • ALK-Abello A/S
    • HollisterStier Allergy（Jubilant Pharma）
    • All Cure Pharma Pvt Ltd
    • Allergopharma GmbH and Co KG
    • HAL Allergy Group
    • LETI Pharma
    • Torii Pharmaceutical Co Ltd
    • Inmunotek SL
    • Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
    • DBV Technologies SA
    • Prota Therapeutics Pty Ltd
    • Stallergenes Greer
    • Allergy Therapeutics pIc
    • Aimmune Therapeutics Inc
    • Others

第12章：分析師視角360度分析

簡介目錄
Product Code: ANV5995

The Drug Desensitization Market size was valued at US$ 602.10 Million in 2024, expanding at a CAGR of 8.07% from 2025 to 2032.

The drug desensitization market includes therapeutic interventions and structured clinical protocols aimed at temporarily increasing patient tolerance to critical medications in people with known hypersensitivity or allergic reactions, allowing them to continue receiving treatment in controlled healthcare settings. The growing prevalence of drug allergies, as well as the increasing reliance on essential first-line therapies such as antibiotics, chemotherapy agents, and biologics for the treatment of serious and life-threatening conditions, are driving market growth. A significant market trend is the shift toward personalized, protocol-based desensitization strategies that are supported by advanced diagnostic tools and patient monitoring technologies. Nonetheless, the requirement for highly trained medical personnel, intensive clinical oversight, and the associated high treatment costs serve as a major constraint. Despite these limitations, rising clinician awareness and the increasing use of biologics and oncology treatments present significant opportunities for the widespread implementation of standardized desensitization programs in hospitals and specialty care settings.

Drug Desensitization Market- Market Dynamics

Rising Prevalence of Drug Hypersensitivity Reactions

The increasing incidence of drug hypersensitivity reactions is a major factor driving global demand for drug desensitization therapies. As the pharmaceutical industry continues to expand into new therapeutic areas, a growing number of patients are experiencing immune-mediated adverse reactions to essential medications, including antibiotics, chemotherapeutic agents, and biologics. These hypersensitivity reactions vary widely in severity, ranging from mild skin rashes to severe, life-threatening allergic responses, posing significant challenges to effective and continuous treatment. According to a March 2023 review article titled "Pathogenesis of Allergic Diseases and Implications for Therapeutic Interventions," drug hypersensitivity reactions account for approximately 5-10% of all adverse drug reactions and affect nearly 7-10% of the global population. While self-reported drug allergies occur in about 8% of individuals, confirmed cases are considerably lower. In pediatric populations, suspected hypersensitivity reactions affect 1-2%, with confirmed cases around 0.05%. Antibiotics remain the most common triggers, responsible for nearly 30% of severe reactions, including Stevens-Johnson syndrome.

Drug Desensitization Market- Segmentation Analysis:

The worldwide market is segmented on the basis of Type, End-Users, Sales Channel, and Region.

In terms of types, Sublingual Immunotherapy (SLIT), with its numerous patient-centered benefits, is now the market leader in global drug desensitization, accounting for 66.1% by 2025. The most significant factor in the patient-friendly benefits is the administration of allergenic extracts or therapeutic agents under the tongue, which patients perform themselves, providing an easy and comfortable way of treatment at home while avoiding the hassle of frequent clinic visits.

In October 2023, the American Academy of Allergy, Asthma, and Immunology (AAAAI) reported that sublingual immunotherapy (SLIT) resulted in 60% desensitization and 48% remission in peanut-allergic children over three years. According to the research, early childhood intervention is a critical factor in facilitating drug desensitization and long-term allergy remission.

Hospitals and specialized allergy clinics are the largest end-users in the global drug desensitization market. This dominance stems from their ability to combine advanced diagnostic capabilities, specialized clinical expertise, and multidisciplinary patient management in controlled healthcare settings. These facilities are uniquely equipped to perform complex drug desensitization procedures by utilizing individualized dosing protocols, continuous patient monitoring, and close supervision by immunology and allergy specialists, ensuring safe, precise, and evidence-based care. The importance of hospitals and specialty clinics in this segment is emphasized by regulatory approvals of advanced desensitization therapies. For example, in February 2024, the United States Food and Drug Administration approved Xolair (omalizumab), developed by Genentech and Novartis, as the first medication shown to reduce allergic reactions to multiple foods after accidental exposure. This approval, which extends the use to adults and children aged one year and older with IgE-mediated food allergies, emphasizes the critical role of hospital-based and specialty clinics in administering and managing advanced desensitization treatments.

Drug Desensitization Market- Geographical Insights

North America represents a significant region in the global drug desensitization market in 2025, supported by its highly advanced healthcare infrastructure, strong concentration of pharmaceutical and biotechnology companies, and supportive government policies that promote innovation in allergy management and immune tolerance therapies. The region also benefits from substantial public and private investments in research and development, which continue to drive therapeutic advancements and clinical adoption. For example, in September 2025, ARS Pharmaceuticals, a U.S.-based biopharmaceutical company, received regulatory approval in Japan for Neffy, the first and only needle-free epinephrine nasal spray indicated for the emergency treatment of allergic reactions and anaphylaxis. Developed in collaboration with Alfresa Holdings, which will commercialize the product in Japan, Neffy is expected to be available in the fourth quarter of 2025 for adults and pediatric patients weighing more than 15 kilograms.

United States Drug Desensitization Market- Country Insights

The U.S. drug desensitization market remains the largest globally, supported by substantial investments in research and development, advanced healthcare infrastructure, and a high prevalence of drug and food sensitivities among patients. The strong presence of leading pharmaceutical companies such as Regeneron Pharmaceuticals and Horizon Therapeutics, along with well-established specialized allergy treatment centers, is accelerating the adoption of advanced desensitization protocols across the country. For instance, in September 2023, Nestle divested its peanut allergy treatment Palforzia to U.S.-based Stallergenes Greer, a recognized leader in allergen immunotherapy and drug desensitization. Palforzia, the first oral therapy approved by the U.S. FDA for peanut allergy, was originally acquired by Nestle in 2020 for USD 2.1 billion but experienced limited commercial uptake. This acquisition positioned Stallergenes Greer as the first company to offer therapies for both respiratory and food allergies, while enabling Nestle to refocus its strategic priorities on gastrointestinal treatments.

Drug Desensitization Market- Competitive Landscape:

The drug desensitization market is moderately consolidated, with established pharmaceutical companies, specialized allergy therapy providers, and emerging biotech firms specializing in immunology and hypersensitivity management. Market participants compete by developing new products, expanding clinical indications, and forming strategic alliances with hospitals and specialty allergy clinics. Companies are increasing their investment in research and development to improve desensitization protocols, improve patient safety, and broaden applications for food, drug, and biologic allergies. Regulatory approvals and acquisitions remain critical strategies for improving market positioning and expanding product portfolios. Leading players in the market include ALK-Abello A/S, HollisterStier Allergy (Jubilant Pharma), All Cure Pharma Pvt Ltd, and Allergopharma GmbH and Co KG. They use clinical expertise and global distribution networks to maintain a competitive edge and drive market growth.

Recent Developments:

In February 2025, ALK-AbellA/S, a Danish-based global specialty pharmaceutical company specializing in allergy immunotherapy and allergic asthma, has received FDA approval for its DACTRAtablet to treat house dust mite-induced allergic rhinitis in children aged five to eleven. This expands its previous approval for patients aged twelve to sixty-five and strengthens ALK's position in drug desensitization therapy.

In January 2025, Stallergenes Greer, a Swiss biopharmaceutical company that specializes in allergen immunotherapy, has received European Commission approval to extend Palforzia for the treatment of toddlers aged one to three who have a confirmed peanut allergy. Palforzia, the first oral drug desensitization therapy approved by the EMA and the FDA for this age group, promotes tolerance to peanut allergens and reduces the risk of severe allergic reactions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DRUG DESENSITIZATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • IDEXX Laboratories Inc
  • ALK-Abello A/S
  • HollisterStier Allergy (Jubilant Pharma)
  • All Cure Pharma Pvt Ltd
  • Allergopharma GmbH and Co KG
  • HAL Allergy Group
  • LETI Pharma
  • Torii Pharmaceutical Co Ltd
  • Inmunotek S.L.
  • Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
  • DBV Technologies SA
  • Prota Therapeutics Pty Ltd
  • Stallergenes Greer
  • Allergy Therapeutics pIc
  • Aimmune Therapeutics Inc
  • Others

GLOBAL DRUG DESENSITIZATION MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)
  • Other emerging immunotherapy delivery methods

GLOBAL DRUG DESENSITIZATION MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032

  • Outpatient treatment centers
  • Hospitals and specialty allergy clinics
  • Homecare settings
  • Others

GLOBAL DRUG DESENSITIZATION MARKET, BY SALES CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Channel
  • Offline Channel

GLOBAL DRUG DESENSITIZATION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Drug Desensitization Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Drug Desensitization Market Snippet by Type
    • 2.1.2. Drug Desensitization Market Snippet by End-Users
    • 2.1.3. Drug Desensitization Market Snippet by Sales Channel
    • 2.1.4. Drug Desensitization Market Snippet by Country
    • 2.1.5. Drug Desensitization Market Snippet by Region
  • 2.2. Competitive Insights

3. Drug Desensitization Key Market Trends

  • 3.1. Drug Desensitization Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Drug Desensitization Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Drug Desensitization Market Opportunities
  • 3.4. Drug Desensitization Market Future Trends

4. Drug Desensitization Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Drug Desensitization Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Drug Desensitization Market Landscape

  • 6.1. Drug Desensitization Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Drug Desensitization Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Subcutaneous Immunotherapy (SCIT)
    • 7.1.3. Sublingual Immunotherapy (SLIT)
    • 7.1.4. Other emerging immunotherapy delivery methods

8. Drug Desensitization Market - By End-Users

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
    • 8.1.2. Outpatient treatment centers
    • 8.1.3. Hospitals and specialty allergy clinics
    • 8.1.4. Homecare settings
    • 8.1.5. Others

9. Drug Desensitization Market - By Sales Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Sales Channel, 2024 & 2032 (%)
    • 9.1.2. Online Channel
    • 9.1.3. Offline Channel

10. Drug Desensitization Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Drug Desensitization Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Drug Desensitization Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Drug Desensitization Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Drug Desensitization Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Drug Desensitization Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Drug Desensitization Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. IDEXX Laboratories Inc
    • 11.2.2. ALK-Abello A/S
    • 11.2.3. HollisterStier Allergy (Jubilant Pharma)
    • 11.2.4. All Cure Pharma Pvt Ltd
    • 11.2.5. Allergopharma GmbH and Co KG
    • 11.2.6. HAL Allergy Group
    • 11.2.7. LETI Pharma
    • 11.2.8. Torii Pharmaceutical Co Ltd
    • 11.2.9. Inmunotek S.L.
    • 11.2.10. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
    • 11.2.11. DBV Technologies SA
    • 11.2.12. Prota Therapeutics Pty Ltd
    • 11.2.13. Stallergenes Greer
    • 11.2.14. Allergy Therapeutics pIc
    • 11.2.15. Aimmune Therapeutics Inc
    • 11.2.16. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us